Mangaluru: Aiming to contribute a breakthrough in Alzheimer’s disease (AD) treatment, Mangaluru girl Salwa has successfully completed her Ph.D. in a unique area of pharmaceutical research focused on developing lipid nano-carriers for oral delivery of an anti-Alzheimer’s drug. Her research offers promising advancements in the treatment of AD, a condition affecting millions globally and growing in prevalence.
Guided by Dr. Lalit Kumar, former Assistant Professor of Pharmaceutics, and co-guided by Dr. C Mallikarjuna Rao, Professor of Pharmacology, both from the Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Salwa’s work addresses the urgent need for more effective drug delivery mechanisms to treat Alzheimer’s beyond temporary relief.
Alzheimer’s, a progressive neurodegenerative disease, has been challenging to treat due to limited therapeutic options, especially those capable of effectively reaching the brain. Her research seeks to improve brain-targeted drug delivery using lipid nano-carriers, potentially offering a scalable, industry-ready solution that could change the approach toward treating Alzheimer’s disease and provide real improvements in quality of life for patients.
The young researcher has a strong academic background, having qualified for the Graduate Pharmacy Aptitude Test (GPAT) with an All India Rank (AIR) of 724, which earned her a fellowship for postgraduate studies. She was awarded a prestigious National Doctoral Fellowship (NDF) from the All India Council for Technical Education (AICTE) and received intramural research funding from Manipal Academy of Higher Education (MAHE) for her Ph.D. research.
Throughout her doctoral journey, Salwa received multiple honors, including travel grants from the Indian Council of Medical Research (ICMR), the University of Toronto, and the International Brain Research Organization (IBRO). She was also a recipient of the PRAISE award for two consecutive years (2022 and 2023), alongside numerous research publications and patents.
Her parents, the late Abdul Samad and Sahira Banu, and her siblings have been an enduring inspiration throughout her academic and research journey. The young researcher’s future plans include furthering her work to explore how her developed nano-carrier system could support neuronal regeneration, potentially advancing Alzheimer’s treatment options for millions worldwide.
Let the Truth be known. If you read VB and like VB, please be a VB Supporter and Help us deliver the Truth to one and all.
New Delhi, Nov 22: Flipkart's co-founder Binny Bansal has stepped down from the board of PhonePe, the fintech company said on Friday.
PhonePe also announced the appointment of Manish Sabharwal as an Independent Director and Chair of its Audit Committee.
In this role, Sabharwal will be instrumental in upholding the integrity and effectiveness of PhonePe's financial reporting, internal controls, and risk management practices, he company said in a release.
"PhonePe also announced that Flipkart's co-founder, Binny Bansal has stepped down from its Board of Directors. Binny acquired PhonePe in 2016 and has been on its Board since then," the release said.
Commenting on the board rejig, Sameer Nigam, CEO and Founder of PhonePe said, "I would like to express my heartfelt gratitude to Binny Bansal for being one of PhonePe's earliest and staunchest supporters. His active engagement, strategic guidance, and personal mentorship have profoundly enriched our discussions. Binny will be missed!"
Nigam further said that Sabharwal's depth of understanding of India's macro economy, coupled with his leadership in shaping India's policies for education, employment, and employability will be invaluable as PhonePe continues to work ahead towards shared vision of a Viksit Bharat by 2047.
Sabharwal is Vice-Chairman of Teamlease Services, India's largest staffing and human capital firm.
Bansal played an instrumental role in Flipkart's acquisition of PhonePe way back in 2016 and had been on its board since then (the payments firm separated from Flipkart in 2022).